Tecnotree Reports Consistent Revenue, Margin Expansion and Three Consecutive Quarters Of Positive Free Cashflow
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the fourth quarter and full year of 2024. 2024 was a pivotal year for Tecnotree despite macro economic challenges, the company delivered 3 consecutive quarters of positive free cash flow achieving and strong ARR growth by 8% YoY from 2023. Further the company delivered on the guidance previously announced achieving a revenue increase of 4% YoY in constant currency, an increase of EBIT of 9% YoY in constant currency and an increase in Free Cash Flow by 7.9 Million Euro in 2024 from the previous period. In 2024, the company’s strategic cost optimization achieved higher savings than previously committed. Tecnotree had taken precautionary measures and made adequate provisions to exit markets which are characterised with geo-political risks, areas of conflict or regions with high risks of sanctions. Further, Tecnotree achieved a breakthrough Tier 1 telco deal in the United States, in collaboration with a leading Systems Integrator (SI) as previously announced, validating our investment in TM Forum Standards and our ability to secure recurring revenue streams in Dollar denominated enterprise markets, paving the way for sustainable growth in the future.
Q4 Results
-
Net sales of EUR 17.6 million (22.2) -20.7% Year on Year, In constant currency,
-16.5% Year on Year. - Operating profit of EUR 10.9 million (7.9) +38.1% Year on Year.
- Operating margin of 61.7% (35.4%).
- Foreign exchange losses reduced EUR 0.3 million (6.0).
- Net income for the quarter was EUR 0.5 million (2.4) -79% Year on Year.
- Adjusted net income for quarter EUR 4.9 million (2.4) +104% Year on Year.
- Gross cash inflow from operating activities EUR 8.4 million (9.9).
- Positive free cash flow of EUR 0.4 million (-0.6), the third quarter in a row.
- Earnings per share EUR 0.03 (0.01*).
- Order book at the end of the period EUR 79.6 million (80.2).
Full year Results
- Net sales of EUR 71.6 million (78.4) –8.6% Year on Year, in constant currency +4.0% Year on Year, in line with guidance.
- Operating profit EUR 23.8 million (23.8) flat Year on Year, however operating profit margin expanded to 33.2% (30.4%). Operating profit in constant currency EUR 26.0 million, +9.0 % Year on Year in line with guidance.
- Foreign exchange losses reduced to EUR 2.5 million (9.7).
- Net Income for the period EUR 8.3 million (11.2) -25.8% Year on Year due to one-time items pertaining to EUR 7.3 million.
- Adjusted net income was EUR 15.6 million (11.2) +39.3% Year on Year.
- Gross cash inflow from operating activities EUR 21.3 million (17.4).
- Free cash flow stands at EUR -1.8 million ( -9.7).
- Free cash flow for H2 stands at EUR 2.2 million (-3.9) in line with guidance.
- Earnings per share were EUR 0.5 (0.04*).
"Tecnotree’s SISU-driven execution has delivered a pivotal year of transformation, resilience, and growth. With three consecutive quarters of positive free cash flow, a landmark Tier 1 telco deal in the U.S., and a strengthened focus on AI-powered automation, we have reinforced our financial position and market leadership. Our cost optimization initiatives exceeded expectations, while our ARR expansion and strategic shift to Tier 1 and dollar-denominated markets ensure a scalable and profitable future. As we step into 2025, we remain committed to driving AI-led innovation, sustainable growth, and delivering long-term value to our investors and customers."
– Padma Ravichander, CEO, Tecnotree
Significant milestones and business achievements for the year included:
- Tecnotree Increased productivity from AI/ML consistently executing 5-7 digital transformations per quarter, reinforcing our ability to scale revenue with efficiency.
- 2024 Gartner® Magic Quadrant for AI in CSPs – A first-time recognition for our AI-driven telco transformations.
- Among the Top 2 Global Telecom Revenue Management Providers (Precision Reports, for the 2nd consecutive year.
- Featured in 4 Gartner® HypeCycles & 2 Gartner® Market Guides for CSP digital marketplaces, revenue management, and Customer Management solutions.
- Named one of the fastest-growing BSS providers by Omdia in 2024, highlighting our momentum against legacy competitors.
- In 2024 Tecnotree for the second consecutive year was recognized as a top-performing company in the Nordic Business Diversity Index (Mid-Cap Segment), reinforcing our commitment to building inclusive, digitally connected communities while delivering strong financial outcomes.
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company's commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226249918/en/
Contacts
Prianca Ravichander, Tecnotree CMO
Email: marketing@tecnotree.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom